469.2500 -10.75 (-2.24%)
NSE May 30, 2025 15:31 PM
Volume: 917.1K
 

469.25
-2.24%
Reliance Securities
Revenue from pharma business grew by 3% YoY. Notably, the segment recorded its highest therapies i.e. antihypertensive, cardiovascular, oncology and corticosteroids etc. The company also has a strong pipeline of approvals and visibility to maintain growth momentum. Segmental EBIT grew by 20% YoY in 3QFY20, and we expect similar growth in 4QFY20E as well. Specialty Chemical Biz Slight Decline in Margin...
Aarti Industries Ltd. is trading below its 200 day SMA of 472.8
More from Aarti Industries Ltd.
Recommended